FDA 483 - Sajjad A. Sabir, M.D. - May 23, 2024

An FDA inspection of Sajjad A. Sabir, M.D., a clinical investigator in Camden, NJ, revealed significant deficiencies in record-keeping and adherence to investigational plans. Observations included documenting study visits for deceased subjects and failing to properly report adverse events and conduct follow-up visits according to protocol. These issues indicate serious concerns regarding data integrity and patient safety in clinical trials.